Analyst coverage for Clinuvel Pharmaceuticals (ASX: CUV) from prominent independent financial research groups and investment banks maintains a consistent Buy stance. Experts point to the firm's strong underlying EBITDA margins, defensive cash positioning, and proprietary peptide technology portfolio as justification for positive long-term investment ratings.